O
OrbiMed Portfolio holdings
AUM
$5.4B
Turnover
40.13%
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+30.69%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.46B
AUM Growth
+$453M
(+9%)
Cap. Flow
-$312M
Cap. Flow
% of AUM
-5.72%
Top 10 Holdings %
Top 10 Hldgs %
38.94%
Holding
132
New
22
Increased
22
Reduced
29
Closed
18
Avg Time Held Equity + Options
2.6
years
Top 10 Avg Time Held Equity + Options
0.9
years
Top 20 Avg Time Held Equity + Options
1.3
years
Avg Time Held Equity only
2.6
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ArriVent BioPharma
AVBP
|
+$61.1M |
| 2 |
Cytokinetics
CYTK
|
+$52.8M |
| 3 |
Esperion Therapeutics
ESPR
|
+$33.3M |
| 4 |
Merck
MRK
|
+$32.2M |
| 5 |
Q32 Bio
QTTB
|
+$31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RayzeBio, Inc. Common Stock
RYZB
|
+$147M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$93.5M |
| 3 |
United Therapeutics
UTHR
|
+$84.9M |
| 4 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
+$71.7M |
| 5 |
SpringWorks Therapeutics
SWTX
|
+$69.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.1% |
| 2 | Miscellaneous | 0.9% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
NextCure
NXTC
$29.8M
| $2.54M | 0.05% |
95,100
-130,818
| -58% | -$2.25M |
2019 Q2
19 quarters
|
|
102
Bolt Biotherapeutics
BOLT
$7.78M
| $2.16M | 0.04% |
77,050
| – | – |
2022 Q3
6 quarters
|
|
|
HLSQ
103
Tessera Defense and Homeland Security Inc.
HLSQ
$2.24M
| $2.03M | 0.04% |
2,378
| – | – |
2019 Q4
17 quarters
|
|
104
Chemomab Therapeutics
CMMB
$9.38M
| $1.75M | 0.03% |
560,319
| – | – |
2021 Q1
12 quarters
|
|
105
DELISTED
Kezar Life Sciences
KZR
| $1.74M | 0.03% |
192,700
| – | – |
2022 Q2
7 quarters
|
|
106
DELISTED
Vigil Neuroscience
VIGL
| $1.53M | 0.03% |
448,891
| – | – |
2022 Q1
8 quarters
|
|
107
DELISTED
Dynavax Technologies
DVAX
| $1.41M | 0.03% |
+113,500
| New | +$1.48M |
2024 Q1
0 quarters
|
|
108
CalciMedica
CALC
$7.37M
| $1.24M | 0.02% |
59,476
| – | – |
2023 Q2
3 quarters
|
|
|
LSB
109
DELISTED
LakeShore Biopharma
LSB
| $1.1M | 0.02% |
153,443
-170,188
| -53% | -$867K |
2023 Q1
4 quarters
|
|
110
DELISTED
Acutus Medical Inc
AFIB
| $498K | 0.01% |
2,648,386
| – | – |
2020 Q3
14 quarters
|
|
111
Lyell Immunopharma
LYEL
$187M
| $445K | 0.01% |
+9,975
| New | +$427K |
2024 Q1
0 quarters
|
|
112
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $278K | 0.01% |
18,023
| – | – |
2021 Q2
11 quarters
|
|
113
Xeris Biopharma Holdings
XERS
$1.85B
| $178K | ﹤0.01% |
+80,420
| New | +$208K |
2024 Q1
0 quarters
|
|
114
Agios Pharmaceuticals
AGIO
$1.84B
| – | – |
-45,000
| Closed | -$1M | – |
|
115
Alnylam Pharmaceuticals
ALNY
$30.1B
| – | – |
-79,400
| Closed | -$15.2M | – |
|
116
Celldex Therapeutics
CLDX
$2.2B
| – | – |
-58,800
| Closed | -$2.33M | – |
|
117
Gilead Sciences
GILD
$190B
| – | – |
-100,000
| Closed | -$8.1M | – |
|
118
Humana
HUM
$51.5B
| – | – |
-109,900
| Closed | -$50.3M | – |
|
119
Illumina
ILMN
$40.5B
| – | – |
-31,148
| Closed | -$4.22M | – |
|
120
Iovance Biotherapeutics
IOVA
$6.52B
| – | – |
-4,707,458
| Closed | -$38.3M | – |
|
121
CALL
Pfizer
PFE
$168B
| – | – |
-500,000
| Closed | -$14.4M | – |
|
122
uniQure
QURE
$1.43B
| – | – |
-1,347,900
| Closed | -$9.13M | – |
|
123
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-35,177
| Closed | -$6.99M | – |
|
124
Arcus Biosciences
RCUS
$2.89B
| – | – |
-117,000
| Closed | -$2.23M | – |
|
|
125
United Therapeutics
UTHR
$23.4B
| – | – |
-386,100
| Closed | -$84.9M | – |
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q1 2024 Portfolio in Review
As of Q1 2024, OrbiMed held 132 positions worth $5.46B, up 9% from $5.01B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
OrbiMed withdrew a net $312M in Q1 2024, closing 18 positions and reducing 29 holdings. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $147M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, OrbiMed opened a new position in ArriVent BioPharma worth $54.1M.
- OrbiMed's largest Q1 2024 buy was ArriVent BioPharma: 3,027,328 shares worth $54.1M.
- OrbiMed added most to Merck in Q1 2024, an estimated $32.2M increase.
- OrbiMed's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $69.9M.
- OrbiMed fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $147M.
- OrbiMed's ten largest holdings make up 39% of its $5.46B portfolio in Q1 2024.
- OrbiMed opened 22 new positions and closed 18 in Q1 2024.
- OrbiMed's portfolio value rose 9% quarter-over-quarter to $5.46B.
Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.